Opin vísindi

Serum levels of ACE2 are higher in patients with obesity and diabetes

Serum levels of ACE2 are higher in patients with obesity and diabetes


Title: Serum levels of ACE2 are higher in patients with obesity and diabetes
Author: Emilsson, Valur   orcid.org/0000-0001-9982-0524
Guðmundsson, Elías F.
Aspelund, Thor   orcid.org/0000-0002-7998-5433
Jónsson, Brynjólfur G.
Guðjónsson, Alexander
Launer, Lenore J.
Lamb, John R.
Guðmundsdóttir, Valborg
Jennings, Lori L.
Guðnason, Vilmundur G.
Date: 2020-12-16
Language: English
Scope: 5
Department: Faculty of Medicine
Series: Obesity Science and Practice; 7(2)
ISSN: 2055-2238
DOI: https://doi.org/10.1002/osp4.472
Subject: Blóðvatn; Offita; Sykursýki; COVID-19; Endocrinology, Diabetes and Metabolism; Nutrition and Dietetics
URI: https://hdl.handle.net/20.500.11815/2896

Show full item record

Citation:

Emilsson , V , Guðmundsson , E F , Aspelund , T , Jónsson , B G , Guðjónsson , A , Launer , L J , Lamb , J R , Guðmundsdóttir , V , Jennings , L L & Guðnason , V G 2020 , ' Serum levels of ACE2 are higher in patients with obesity and diabetes ' , Obesity Science and Practice , vol. 7 , no. 2 , pp. 239-243 . https://doi.org/10.1002/osp4.472

Abstract:

Objective: As severity of outcome in COVID-19 is disproportionately higher among individuals with obesity, smokers, patients with hypertension, kidney disease, chronic pulmonary disease, coronary heart disease (CHD), and/or type 2 diabetes (T2D), serum levels of ACE2, the cellular entry point for the coronavirus SARS-CoV-2, were examined in these high-risk groups. Methods: Associations of ACE2 levels to smokers and patients with hypertension, T2D, obesity, CHD, or COPD were investigated in a single center population-based study of 5457 Icelanders from the Age, Gene/Environment Susceptibility Reykjavík Study (AGES-RS) of the elderly (mean age 75 ± 6 years), using multiple linear regression analysis. Results: Serum levels of ACE2 were higher in smokers and individuals with T2D and/or obesity while they were unaffected in the other patient groups. Conclusion: ACE2 levels are higher in some patient groups with comorbidities linked to COVID-19 including obesity and T2D and as such may have an emerging role as a circulating biomarker for severity of outcome in the disease.

Description:

© 2020 The Authors. Obesity Science & Practice published by World Obesity and The Obesity Society and John Wiley & Sons Ltd.

Files in this item

This item appears in the following Collection(s)